NeoPharm CO. LTD (092730) — Cash Flow Reinvestment Rate
NeoPharm CO. LTD (092730) has a Cash Flow Reinvestment Rate of 0.25x as of September 2025, reinvesting ₩1.45 Billion (capex ₩446.60 Million plus investments ₩-1.00 Billion) from operating cash flow of ₩5.88 Billion. Explore NeoPharm CO. LTD capital reinvestment ratio to see what proportion of operating cash flow is directed to capital expenditures.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
NeoPharm CO. LTD Cash Flow Reinvestment Rate (2012–2024)
Historical reinvestment intensity for NeoPharm CO. LTD across 11 annual periods. Also explore total assets of NeoPharm CO. LTD for the complete picture of this company's asset base.
Annual Cash Flow Reinvestment Rate for NeoPharm CO. LTD (2012–2024)
Year-by-year capital reinvestment analysis for NeoPharm CO. LTD. For live market cap and broader valuation context, see 092730 company net worth.
| Year | Reinvestment Rate | Total Reinvested (KRW) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 0.50x | ₩9.30 Billion | ₩18.63 Billion | ₩3.08 Billion | ▼ -68.8% |
| 2023 | 1.60x | ₩37.18 Billion | ₩23.26 Billion | ₩20.83 Billion | ▲ +202.2% |
| 2022 | 0.53x | ₩9.61 Billion | ₩18.16 Billion | ₩806.43 Million | ▼ -29.7% |
| 2021 | 0.75x | ₩16.32 Billion | ₩21.68 Billion | ₩320.11 Million | ▲ +199.9% |
| 2020 | 0.25x | ₩4.29 Billion | ₩17.07 Billion | ₩285.62 Million | ▼ -90.7% |
| 2019 | 2.70x | ₩51.90 Billion | ₩19.22 Billion | ₩5.90 Billion | ▲ +398.5% |
| 2018 | 0.54x | ₩8.76 Billion | ₩16.18 Billion | ₩1.94 Billion | ▼ -48.2% |
| 2017 | 1.05x | ₩11.13 Billion | ₩10.65 Billion | ₩884.71 Million | ▲ +17.2% |
| 2016 | 0.89x | ₩8.17 Billion | ₩9.16 Billion | ₩1.40 Billion | ▲ +133.3% |
| 2015 | 0.38x | ₩2.33 Billion | ₩6.09 Billion | ₩786.89 Million | ▼ -81.5% |
| 2012 | 2.06x | ₩1.16 Billion | ₩564.34 Million | ₩172.47 Million | — |